Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader

These articles are all highly relevant Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader. I believe this information can help you understand Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
2022
DATE
09 - 14
Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader
Revenue hit $242 million, up 96.2% y-o-y.Net profit reached $92 million, up 56.67% y-o-y.R&D investment stood at $23 million, up 85.72% y-o-y. Vazyme recently released the 2022 semi-annual report, revealing the robust growth in the first half of the year. Vazyme has been stepping up R&D efforts over
Read More

Subscribe to our Newsletter

Our vision is to lead in biotechnology by driving innovation relentlessly, pursuing the highest standards in quality of products and services, and creating value for our customers.

OUR PRODUCTS

MORE LINKS

CONTACT US

Address: Building D2, Hongfeng science and
Technology Park, Kechuang Road, Nanjing
Economic and Technological Development
Zone, Jiangsu Province, China
Tel:+86 400-168-5000
E-mail: medical@vazyme.com
Copyright @ 2022 Nanjing Vazyme Biotech Co.,Ltd. All Rights Reserved